Ischemic Stroke
Conditions
Keywords
Neu2000KWL, Neuroprotection, endovascular therapy, glutamate, free radical
Brief summary
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 12 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.
Detailed description
Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+ -permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has been well demonstrated in four animal models of stroke with better efficacy and therapeutic time windows than either NMDA receptor antagonist or anti-oxidant advanced to clinical trials. In human phase I studies of 165 healthy subjects conducted in the United States and China, Neu2000KWL showed promising safety profiles without any serious adverse events up to a single intravenous infusion of 6000 mg that is far beyond the therapeutic target dose determined in animal models of transient ischemic stroke. Very recently, acute endovascular recanalization therapy has been introduced as the new standard care of care in acute ischemic stroke. The present study is aimed to examine efficacy and safety of Neu2000KWL in acute ischemic stroke patients receiving endovascular thrombectomy within 12 hours of stroke onset. This is a randomized trial, with placebo comparison, of comparing functional outcome at week 12 after 10 times of administration for five days.
Interventions
DRUGNeu2000KWL group
1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
DRUGPlacebo group
1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
Sponsors
GNT Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The trial subjects should satisfy all the following criteria. 1. Adults≥19 years 2. Patients who can start endovascular therapy within 12 hours after the symptomatic onset of Ischemic stroke. 3. NIHSS on screening time point ≥ 8 points 4. Patients whose general condition was favorable enough to perform daily activities without the help of others one day prior to the ischemic stroke onset (a person with mRS 0 or 1) 5. Patients whose CTA or MRA confirmed internal carotid artery occlusion and M1 or M2 occlusion of the middle cerebral artery, that are the types of major cerebral artery occlusion that can cause acute cerebral infarction and are subject to endovascular therapy. 6. Patients with early ASPECTS point≥4 (Noncontrast brain cross-section CT or Brain cross-section MRI diffusion weighted imaging) 7. Patients who spontaneously submitted a written informed consent to participation on this clinical study.
Exclusion criteria
A patient who meets any one of the conditions below cannot participate in the Clinical trial. 1. Patients who meet the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS score evaluated at 12 week after the first dose of drug (Nelonemdaz or Placebo). | week12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of mRS 0-2 evaluated at week 5 and week 12 after the first dose of drug (Nelonemdaz or Placebo). | week5, week12 | — |
| mRS score evaluated at week 5 after the first dose of investigational drug (Nelonemdaz or Placebo). | week5 | — |
| Proportion of mRS 0 measured at week 5 and week 12 after the first dose of investigational drug (Nelonemdaz or Placebo). | week5, week12 | — |
| Proportion of NIHSS 0-4 evaluated within 24 hours (Within 72 hours if weekend is included), 5 week, 12 week after the last injection of drug. (Evaluating 43 points for deaths) | 24hour(or 72hour), week5, week12 | — |
| Proportion of Barthel Index≥95 evaluated at week 5 and week 12 | week5, week12 | — |
| Occurrence rate of Symptomatic intracranial hemorrhage (SICH) described and defined by this study occurring within 24 hours after the last injection | 24hour | \[Definition of Symptomatic intracranial hemorrhage (SICH)\] In the case that brain imaging confirms intracranial hemorrhage with neurological deterioration. (NIHSS score≥4 points) neurological deterioration. (NIHSS score≥4 points) |
| Volume of Ischemic stroke based on brain MRI diffusion weighted imaging within 24 hours and at week 12. (If MRI is not available, reading will be performed based on CT scan.) | 24hour, week12 | — |
Other
| Measure | Time frame |
|---|---|
| Proportion of adverse events and serious adverse events | day0~week12 |
| All mortality rate until 12 weeks | day0~week12 |
Countries
South Korea
Contacts
Primary ContactChun San An
Outcome results
None listed